Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 243 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: n-Acetylcysteine Clear all
Enrolling by invitation Phase 2 Interventional

DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury

NCT07567274
View directory record Official record
Conditions
Tinnitus
Interventions
DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine
Drug
Lead sponsor
Leading Edge Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 24, 2026, 1:26 AM EDT
Recruiting Early Phase 1 Interventional

Imaging Acetadote Metabolism in Glioblastoma

NCT07387666
View directory record Official record
Conditions
Glioblastoma, GBM
Interventions
Acetadote
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 24, 2026, 1:26 AM EDT
Completed No phase listed Observational

Treatment of APAP Toxicity With IV and Oral NAC 2008-2011

NCT01465542
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
1 Month to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine in Alcohol Dependence

NCT00568087
View directory record Official record
Conditions
Alcoholism
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Study of N-Acetyl Cysteine in Children With Autism

NCT00676195
View directory record Official record
Conditions
Autistic Disorder
Interventions
N-Acetyl Cysteine
Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease

NCT01427517
View directory record Official record
Conditions
Parkinson's Disease, Gaucher's Disease
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Translational Neuropsychopharmacology Research of Nicotine Addiction

NCT02723162
View directory record Official record
Conditions
Nicotine Dependence, Cigarettes
Interventions
Varenicline (VRN), N-Acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Sep 24, 2026, 1:26 AM EDT
Withdrawn Phase 4 Interventional

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

NCT02719392
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression
Interventions
N-acetylcysteine, Minocycline, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 24, 2026, 1:26 AM EDT
Terminated Phase 3 Interventional Results available

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

NCT02411084
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Begelomab, Conventional Second-line Treatment
Biological
Lead sponsor
Adienne SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available

Signatures of N-Ac for Non-Suicidal Self-Injury in Adolescents

NCT04005053
View directory record Official record
Conditions
Self-Harm, Depression, Suicide
Interventions
N-acetyl cysteine, Placebo oral tablet
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 24, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Rifaximin With NAC in IBS-D

NCT06727422
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Interventions
rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Not applicable Interventional

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

NCT00889538
View directory record Official record
Conditions
Autism, Severe Behavior Disorder
Interventions
placebo, glutathione, glutathione, vit C and NAC
Drug
Lead sponsor
University of Louisville
Other
Eligibility
5 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available

Use of N-Acetylcysteine (NAC) in Fingernail Biting

NCT01993849
View directory record Official record
Conditions
Onychophagia
Interventions
N-Acetylcysteine (NAC), Placebo
Drug · Other
Lead sponsor
Kevin Gray, MD
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Early Phase 1 Interventional

Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder

NCT03120468
View directory record Official record
Conditions
Alcoholism
Interventions
Topiramate and N-Acetyl Cysteine, Topiramate and Placebo
Drug
Lead sponsor
Nassima Ait-Daoud Tiouririne
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 24, 2026, 1:26 AM EDT
Not yet recruiting Phase 2 Interventional

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

NCT04381897
View directory record Official record
Conditions
Cornelia de Lange Syndrome
Interventions
N-acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Serious Adverse Events Following Angiography

NCT01467466
View directory record Official record
Conditions
Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions
IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 1 Interventional

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

NCT01381354
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil
Other · Device · Dietary Supplement + 1 more
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo

NCT01612221
View directory record Official record
Conditions
Patients at Risk for Melanoma
Interventions
N-acetylcysteine, Placebo arm
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

NCT02583672
View directory record Official record
Conditions
Gaucher Disease Type 1
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 24, 2026, 1:26 AM EDT
Completed No phase listed Observational

Treatment of Acetaminophen Toxicity With N-acetylcysteine

NCT00725179
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Sep 24, 2026, 1:26 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of N-acetylcysteine in Patients With COVID-19 Infection

NCT04374461
View directory record Official record
Conditions
Covid-19
Interventions
N-acetylcysteine, Peripheral Blood
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine (NAC) for Children With Tourette Syndrome

NCT01172288
View directory record Official record
Conditions
Tourettes Syndrome, Tic
Interventions
N-Acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 24, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

NCT03500627
View directory record Official record
Conditions
Healthy
Interventions
OP-101
Drug
Lead sponsor
Orpheris, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 24, 2026, 1:26 AM EDT